{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:34:39Z","timestamp":1776512079912,"version":"3.51.2"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Evidence that antihypertensive medication (AHTN) use is associated with an increased risk of kidney cancer (KC) is emerging. However, limited evidence is available on disentangling the effects of AHTN use on KC from hypertension, which is a risk factor for KC. We aimed to identify pooled estimates for the associations between AHTN use and KC risk, independent of hypertension.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched for observational studies that investigated the associations between AHTN use and KC through January 2025. To identify the independent effects of AHTN from hypertension, we conducted stratified analyses with and without accounting for hypertension: any methods (matching, adjustment, or stratification\/restriction) versus none. We conducted random-effects meta-analyses with robust variance estimation to calculate pooled relative risk (RR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In this meta-analysis consisting of 39 eligible studies, AHTN use was associated with an increased risk of KC based on estimates that accounted for hypertension (RR 1.19, 95% confidence interval (CI) 0.93\u20131.52 for angiotensin-converting enzyme inhibitor; RR 1.15, 95% CI 1.00-1.31 for angiotensin receptor blocker; RR 1.09, 95% CI 1.03\u20131.16 for beta-blocker, RR 1.40, 95% CI 1.12\u20131.75 for calcium channel blocker (CCB); RR 1.36, 95% CI 1.20\u20131.55 for diuretic; and RR 1.40, 95% CI 1.13\u20131.75 for non-classified AHTN). Findings from duration\u2012response relationships supported the main findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>AHTN use was associated with an increased risk of KC compared to no use, even after accounting for hypertension, with the highest risk observed for CCB. Our findings highlight the potential KC risks associated with different AHTN classes, with optimal cardiovascular care remaining an important consideration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14406-3","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T10:48:09Z","timestamp":1749206889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between antihypertensive medication use and kidney cancer risk: a meta-analysis accounting for hypertension"],"prefix":"10.1186","volume":"25","author":[{"given":"Minji","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaekyu","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin I.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin E.","family":"Langston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"14406_CR1","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html. Accessed May 29, 2023."},{"key":"14406_CR2","unstructured":"National Cancer Institute. Annual Report to the Nation 2022: Overall Cancer Statistics. Surveillance, Epidemiology, and End Results Program. Available at: https:\/\/seer.cancer.gov\/report_to_nation\/statistics.html. Accessed June 23, 2023."},{"key":"14406_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3389\/fonc.2019.00859","volume":"9","author":"SH Kim","year":"2019","unstructured":"Kim SH, Park B, Hwang EC, Hong S, Jeong CW, Kwak C, et al. Retrospective multicenter long-term follow-up analysis of prognostic risk factors for recurrence-free, metastasis-free, cancer-specific, and overall survival after curative nephrectomy in non-metastatic renal cell carcinoma. Front Oncol. 2019;9:859.","journal-title":"Front Oncol"},{"key":"14406_CR4","unstructured":"National Cancer Institute. Financial Burden of Cancer Care. Cancer Trends Progress Report. 2022; Available at: https:\/\/progressreport.cancer.gov\/after\/economic_burden. Accessed June 23, 2023."},{"issue":"10","key":"14406_CR5","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):e177\u2013232.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"14406_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","volume":"20","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney cancer, version 3.2022, Nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(1):71\u201390.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"14406_CR7","first-page":"406960","volume":"2014","author":"QN Dinh","year":"2014","unstructured":"Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014(1):406960.","journal-title":"Biomed Res Int"},{"issue":"2","key":"14406_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/ki.2015.89","volume":"88","author":"VH Haase","year":"2015","unstructured":"Haase VH. Inflammation and hypoxia in the kidney: friends or foes? Kidney Int. 2015;88(2):213\u20135.","journal-title":"Kidney Int"},{"issue":"1","key":"14406_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/HJH.0000000000001130","volume":"35","author":"Y Chuang","year":"2017","unstructured":"Chuang Y, Yu M, Huang S, Yang C, Chen C, Lo Y, et al. Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case\u2013control study. J Hypertens. 2017;35(1):170\u20137.","journal-title":"J Hypertens"},{"issue":"4","key":"14406_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10552-017-0857-3","volume":"28","author":"JS Colt","year":"2017","unstructured":"Colt JS, Hofmann JN, Schwartz K, Chow W, Graubard BI, Davis F, et al. Antihypertensive medication use and risk of renal cell carcinoma. Cancer Causes Control. 2017;28(4):289\u201397.","journal-title":"Cancer Causes Control"},{"issue":"6","key":"14406_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/EDE.0000000000001256","volume":"31","author":"KB Kristensen","year":"2020","unstructured":"Kristensen KB, Habel LA, Gagne JJ, Friis S, Andersen KK, Hallas J, et al. Risk of renal cell carcinoma associated with calcium channel blockers: A nationwide observational study focusing on confounding by indication. Epidemiology. 2020;31(6):860\u201371.","journal-title":"Epidemiology"},{"issue":"6","key":"14406_CR12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1161\/HYPERTENSIONAHA.120.14820","volume":"75","author":"CS Kim","year":"2020","unstructured":"Kim CS, Han K, Choi HS, Bae EH, Ma SK, Kim SW. Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study. Hypertension. 2020;75(6):1439\u201346.","journal-title":"Hypertension"},{"key":"14406_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2017.07.001","volume":"83","author":"M Nayan","year":"2017","unstructured":"Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, et al. Medication use and kidney cancer risk: A population-based study. Eur J Cancer. 2017;83:203\u201310.","journal-title":"Eur J Cancer"},{"issue":"9","key":"14406_CR14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/oxfordjournals.aje.a117328","volume":"140","author":"S Weinmann","year":"1994","unstructured":"Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS, White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol. 1994;140(9):792\u2013804.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"14406_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.18632\/aging.102699","volume":"12","author":"Y Xie","year":"2020","unstructured":"Xie Y, Xu P, Wang M, Zheng Y, Tian T, Yang S, et al. Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis. Aging. 2020;12(2):1545.","journal-title":"Aging"},{"issue":"14","key":"14406_CR16","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1096\/fj.03-0129com","volume":"17","author":"T Walther","year":"2003","unstructured":"Walther T, Menrad A, Orzechowski H, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J. 2003;17(14):2061\u20137.","journal-title":"FASEB J"},{"issue":"1\u20132","key":"14406_CR17","first-page":"55","volume":"3","author":"JF Whitfield","year":"1992","unstructured":"Whitfield JF. Calcium signals and cancer. Crit Rev Oncog. 1992;3(1\u20132):55\u201390.","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"14406_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0041-008X(77)90124-7","volume":"40","author":"B Gold","year":"1977","unstructured":"Gold B, Mirvish SS. N-Nitroso derivatives of hydrochlorothiazide, niridazole, and tolbutamide. Toxicol Appl Pharmacol. 1977;40(1):131\u20136.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"14406_CR19","first-page":"68","volume":"15","author":"SH Asar","year":"2016","unstructured":"Asar SH, Jalalpour SH, Ayoubi F, Rahmani MR, Rezaeian M. PRISMA; preferred reporting items for systematic reviews and meta-analyses. J Rafsanjan Univ Med Sci. 2016;15(1):68\u201380.","journal-title":"J Rafsanjan Univ Med Sci"},{"issue":"5","key":"14406_CR20","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/cas.14870","volume":"112","author":"S Matsui","year":"2021","unstructured":"Matsui S, Sobue T, Zha L, Kitamura T, Sawada N, Iwasaki M, et al. Long-term antihypertensive drug use and risk of cancer: the Japan public health Center\u2010based prospective study. Cancer Sci. 2021;112(5):1997\u20132005.","journal-title":"Cancer Sci"},{"key":"14406_CR21","doi-asserted-by":"crossref","unstructured":"Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, DiGaetano R et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011:797\u2013804.","DOI":"10.1097\/EDE.0b013e3182300720"},{"issue":"11","key":"14406_CR22","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1097\/01.hjh.0000186023.74245.48","volume":"23","author":"LJ Schouten","year":"2005","unstructured":"Schouten LJ, van Dijk BA, Oosterwijk E, Hulsbergen-van de Kaa CA, Kiemeney LA, Goldbohm RA, et al. Hypertension, antihypertensives and mutations in the von Hippel\u2013Lindau gene in renal cell carcinoma: results from the Netherlands cohort study. J Hypertens. 2005;23(11):1997\u20132004.","journal-title":"J Hypertens"},{"issue":"4","key":"14406_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S0735-1097(98)00008-4","volume":"31","author":"S Braun","year":"1998","unstructured":"Braun S, Boyko V, Behar S, Reicher-Reiss H, Laniado S, Kaplinsky E, et al. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. J Am Coll Cardiol. 1998;31(4):804\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"14406_CR24","first-page":"351","volume":"77","author":"MC Yu","year":"1986","unstructured":"Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst. 1986;77(2):351\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"14406_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00001648-199701000-00005","volume":"8","author":"RJ Prineas","year":"1997","unstructured":"Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology. 1997;8(1):31\u20136.","journal-title":"Epidemiology"},{"issue":"3","key":"14406_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/bcp.13152","volume":"83","author":"IS Mackenzie","year":"2017","unstructured":"Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol. 2017;83(3):653\u201363.","journal-title":"Br J Clin Pharmacol"},{"key":"14406_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00146885","volume":"3","author":"M McCredie","year":"1992","unstructured":"McCredie M, Stewart JH. Risk factors for kidney cancer in new South wales, australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control. 1992;3:323\u201331.","journal-title":"Cancer Causes Control"},{"issue":"6","key":"14406_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/oxfordjournals.aje.a114476","volume":"124","author":"S Greenland","year":"1986","unstructured":"Greenland S, Thomas DC, Morgenstern H. The rare-disease assumption revisited. A critique of estimators of relative risk for case-control studies. Am J Epidemiol. 1986;124(6):869\u201383.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"14406_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.13105\/wjma.v5.i4.80","volume":"5","author":"C Luchini","year":"2017","unstructured":"Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World J Meta-Analysis. 2017;5(4):80\u20134.","journal-title":"World J Meta-Analysis"},{"issue":"3","key":"14406_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.0950-0804.2005.00249.x","volume":"19","author":"TD Stanley","year":"2005","unstructured":"Stanley TD, Jarrell SB. Meta-regression analysis: a quantitative method of literature surveys. J Economic Surveys. 2005;19(3):299\u2013308.","journal-title":"J Economic Surveys"},{"issue":"11","key":"14406_CR31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","volume":"135","author":"S Greenland","year":"1992","unstructured":"Greenland S, Longnecker MP. Methods for trend Estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135(11):1301\u20139.","journal-title":"Am J Epidemiol"},{"issue":"7109","key":"14406_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"4","key":"14406_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/sim.698","volume":"20","author":"P Macaskill","year":"2001","unstructured":"Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med. 2001;20(4):641\u201354.","journal-title":"Stat Med"},{"issue":"3","key":"14406_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1037\/met0000011","volume":"20","author":"E Tipton","year":"2015","unstructured":"Tipton E. Small sample adjustments for robust variance Estimation with meta-regression. Psychol Methods. 2015;20(3):375.","journal-title":"Psychol Methods"},{"issue":"1","key":"14406_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jrsm.5","volume":"1","author":"LV Hedges","year":"2010","unstructured":"Hedges LV, Tipton E, Johnson MC. Robust variance Estimation in meta-regression with dependent effect size estimates. Res Synthesis Methods. 2010;1(1):39\u201365.","journal-title":"Res Synthesis Methods"},{"key":"14406_CR36","doi-asserted-by":"crossref","unstructured":"Chang P, Huang W, Lin C, Huang T, Wu Y, Chen J et al. Propranolol reduces cancer risk: a population-based cohort study. Medicine 2015;94(27).","DOI":"10.1097\/MD.0000000000001097"},{"issue":"3","key":"14406_CR37","doi-asserted-by":"publisher","first-page":"e0300391","DOI":"10.1371\/journal.pone.0300391","volume":"19","author":"L Chen","year":"2024","unstructured":"Chen L, Yang H, Yu B, Lee M, Lin H, Chiou W, et al. Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study. PLoS ONE. 2024;19(3):e0300391.","journal-title":"PLoS ONE"},{"issue":"4","key":"14406_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/jcm10040771","volume":"10","author":"I Cho","year":"2021","unstructured":"Cho I, Shin J, Jung M, Kang CY, Hwang J, Kwon CH, et al. Antihypertensive drugs and the risk of cancer: a nationwide cohort study. J Clin Med. 2021;10(4):771.","journal-title":"J Clin Med"},{"key":"14406_CR39","doi-asserted-by":"publisher","first-page":"102245","DOI":"10.1016\/j.canep.2022.102245","volume":"80","author":"H Jeon","year":"2022","unstructured":"Jeon H, Lee SH, Nam JH, Shin J. Cancer risk associated with the use of Valsartan in korea: A nationwide cohort study. Cancer Epidemiol. 2022;80:102245.","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"14406_CR40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jch.14187","volume":"23","author":"M Jung","year":"2021","unstructured":"Jung M, Lee J, Lee CJ, Shin J, Kang SH, Kwon CH, et al. Effect of angiotensin receptor blockers on the development of cancer: a nationwide cohort study in Korea. J Clin Hypertens. 2021;23(4):879\u201387.","journal-title":"J Clin Hypertens"},{"issue":"1","key":"14406_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-015-0024-z","volume":"15","author":"PT von Hippel","year":"2015","unstructured":"von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15(1):1\u20138.","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"14406_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"2","key":"14406_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/157488607780598296","volume":"2","author":"G Corrao","year":"2007","unstructured":"Corrao G, Scotti L, Bagnardi V, Sega R. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf. 2007;2(2):125\u201333.","journal-title":"Curr Drug Saf"},{"issue":"3","key":"14406_CR44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/sj.ki.5002650","volume":"73","author":"KJ Jager","year":"2008","unstructured":"Jager KJ, Zoccali C, Macleod A, Dekker FW. Confounding: what it is and how to deal with it. Kidney Int. 2008;73(3):256\u201360.","journal-title":"Kidney Int"},{"issue":"4","key":"14406_CR45","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/aje\/kwm321","volume":"167","author":"S Weikert","year":"2008","unstructured":"Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167(4):438\u201346.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"14406_CR46","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0002-9149(99)00021-1","volume":"83","author":"E Grossman","year":"1999","unstructured":"Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol. 1999;83(7):1090\u20133.","journal-title":"Am J Cardiol"},{"issue":"5","key":"14406_CR47","doi-asserted-by":"publisher","first-page":"C429","DOI":"10.1152\/ajpcell.1983.244.5.C429","volume":"244","author":"MM Walsh-Reitz","year":"1983","unstructured":"Walsh-Reitz MM, Toback FG. Kidney epithelial cell growth is stimulated by Lowering extracellular potassium concentration. Am J Physiology-Cell Physiol. 1983;244(5):C429\u201332.","journal-title":"Am J Physiology-Cell Physiol"},{"issue":"3","key":"14406_CR48","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/074823378700300313","volume":"3","author":"W Lijinsky","year":"1987","unstructured":"Lijinsky W, Reuber MD. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol Ind Health. 1987;3(3):413\u201322.","journal-title":"Toxicol Ind Health"},{"issue":"6","key":"14406_CR49","first-page":"271","volume":"19","author":"TH Riemenschneider","year":"1983","unstructured":"Riemenschneider TH, Bohle A. Morphologic aspects of low-potassium and low-sodium nephropathy. Clin Nephrol. 1983;19(6):271\u20139.","journal-title":"Clin Nephrol"},{"issue":"8","key":"14406_CR50","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/oxfordjournals.eurheartj.a015029","volume":"17","author":"CD Furberg","year":"1996","unstructured":"Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. Eur Heart J. 1996;17(8):1142\u20137.","journal-title":"Eur Heart J"},{"issue":"2","key":"14406_CR51","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1096\/fasebj.9.2.7781924","volume":"9","author":"BF Trump","year":"1995","unstructured":"Trump BF, Berezesky IK. Calcium-mediated cell injury and cell death. FASEB J. 1995;9(2):219\u201328.","journal-title":"FASEB J"},{"issue":"5","key":"14406_CR52","first-page":"5059","volume":"14","author":"P Sobczuk","year":"2017","unstructured":"Sobczuk P, Szczylik C, Porta C, Czarnecka AM. Renin angiotensin system deregulation as renal cancer risk factor. Oncol Lett. 2017;14(5):5059\u201368.","journal-title":"Oncol Lett"},{"issue":"2","key":"14406_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/157488709788185996","volume":"4","author":"A Miyajima","year":"2009","unstructured":"Miyajima A, Kikuchi E, Kosaka T, Oya M. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer. Rev Recen Clin Trial. 2009;4(2):75\u20138.","journal-title":"Rev Recen Clin Trial"},{"issue":"11","key":"14406_CR54","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/pds.1656","volume":"17","author":"TL Assimes","year":"2008","unstructured":"Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf. 2008;17(11):1039\u201349.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"14406_CR55","first-page":"327","volume":"4","author":"W Chow","year":"1995","unstructured":"Chow W, McLaughlin JK, Mandel JS, Wacholder S, Niwa S, Fraumeni JF Jr. Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer epidemiology, biomarkers & prevention: a publication of the American association for Cancer research, cosponsored by the American society of. Prev Oncol. 1995;4(4):327\u201331.","journal-title":"Prev Oncol"},{"key":"14406_CR56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00052431","volume":"4","author":"WD Finkle","year":"1993","unstructured":"Finkle WD, McLaughlin JK, Rasgon SA, Yeoh HH, Low JE. Increased risk of renal cell cancer among women using diuretics in the united States. Cancer Causes Control. 1993;4:555\u20138.","journal-title":"Cancer Causes Control"},{"key":"14406_CR57","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10552-005-0349-8","volume":"16","author":"KT Flaherty","year":"2005","unstructured":"Flaherty KT, Fuchs CS, Colditz GA, Stampfer MJ, Speizer FE, Willett WC, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control. 2005;16:1099\u2013106.","journal-title":"Cancer Causes Control"},{"issue":"4","key":"14406_CR58","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/ije\/19.4.832","volume":"19","author":"GE Fraser","year":"1990","unstructured":"Fraser GE, Phillips RL, Beeson WL. Hypertension, antihypertensive medication and risk of renal carcinoma in California Seventh-Day Adventists. Int J Epidemiol. 1990;19(4):832\u20138.","journal-title":"Int J Epidemiol"},{"key":"14406_CR59","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s10552-009-9375-2","volume":"20","author":"GD Friedman","year":"2009","unstructured":"Friedman GD, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control. 2009;20:1821\u201335.","journal-title":"Cancer Causes Control"},{"issue":"7","key":"14406_CR60","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/sj.bjc.6602490","volume":"92","author":"JP Fryzek","year":"2005","unstructured":"Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, S\u00f8rensen HT, Friis S. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 2005;92(7):1302\u20136.","journal-title":"Br J Cancer"},{"key":"14406_CR61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF01804982","volume":"5","author":"RA Hiatt","year":"1994","unstructured":"Hiatt RA, Tolan K, Quesenberry CP. Renal cell carcinoma and Thiazide use: a historical, case-control study (California, USA). Cancer Causes Control. 1994;5:319\u201325.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"14406_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00004872-199816010-00017","volume":"16","author":"DJ Hole","year":"1998","unstructured":"Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens. 1998;16(1):119\u201324.","journal-title":"J Hypertens"},{"issue":"22","key":"14406_CR63","doi-asserted-by":"publisher","first-page":"e70429","DOI":"10.1002\/cam4.70429","volume":"13","author":"M Jung","year":"2024","unstructured":"Jung M, Li S, Deng Z, Li J, Li M, Basran S, et al. Calcium channel blocker versus Renin\u2013Angiotensin system inhibitor in risk of kidney Cancer among patients with hypertension: A propensity Score-Matched cohort study. Cancer Med. 2024;13(22):e70429.","journal-title":"Cancer Med"},{"key":"14406_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00053150","volume":"4","author":"N Kreiger","year":"1993","unstructured":"Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993;4:101\u201310.","journal-title":"Cancer Causes Control"},{"issue":"5","key":"14406_CR65","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.jhh.1001834","volume":"19","author":"AM Lindgren","year":"2005","unstructured":"Lindgren AM, Nissinen AM, Tuomilehto JO, Pukkala E. Cancer pattern among hypertensive patients in North karelia, Finland. J Hum Hypertens. 2005;19(5):373\u20139.","journal-title":"J Hum Hypertens"},{"issue":"2","key":"14406_CR66","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ijc.2910630212","volume":"63","author":"JK McLaughlin","year":"1995","unstructured":"McLaughlin JK, Chow WH, Mandel JS, Mellemgaard A, McCredie M, Lindblad P, et al. International renal-cell cancer study. VIII. Role of diuretics, other anti\u2010hypertensive medications and hypertension. Int J Cancer. 1995;63(2):216\u201321.","journal-title":"Int J Cancer"},{"issue":"5","key":"14406_CR67","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/ije\/23.5.923","volume":"23","author":"A Mellemgaard","year":"1994","unstructured":"Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLAUGHLIN JK, OLSEN JH. Risk factors for renal cell carcinoma in denmark: role of medication and medical history. Int J Epidemiol. 1994;23(5):923\u201330.","journal-title":"Int J Epidemiol"},{"issue":"13","key":"14406_CR68","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","volume":"279","author":"L Rosenberg","year":"1998","unstructured":"Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, et al. Calcium channel blockers and the risk of cancer. JAMA. 1998;279(13):1000\u20134.","journal-title":"JAMA"},{"issue":"8","key":"14406_CR69","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/aje\/kwm170","volume":"166","author":"VW Setiawan","year":"2007","unstructured":"Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007;166(8):932\u201340.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"14406_CR70","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/oxfordjournals.aje.a009848","volume":"149","author":"JA Shapiro","year":"1999","unstructured":"Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol. 1999;149(6):521\u201330.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"14406_CR71","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/bjc.1998.248","volume":"77","author":"JM Yuan","year":"1998","unstructured":"Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer. 1998;77(9):1508\u201313.","journal-title":"Br J Cancer"},{"issue":"3","key":"14406_CR72","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/annonc\/mdl438","volume":"18","author":"A Zucchetto","year":"2007","unstructured":"Zucchetto A, Dal Maso L, Tavani A, Montella M, Ramazzotti V, Talamini R, et al. History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Ann Oncol. 2007;18(3):596\u2013600.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14406-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14406-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14406-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T18:03:05Z","timestamp":1749232985000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14406-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14406"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14406-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1013"}}